Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
age-related macular degeneration
Biotech
Ocugen eye disease gene therapy nabs underwhelming ph. 2 win
Cutting lesion size by 31% secured a trial victory, but didn't match the 54% figure set by a preliminary analysis.
Darren Incorvaia
Mar 24, 2026 10:40am
Innovent eyes China approval after matching Eylea in phase 3
Mar 24, 2026 6:00am
Kalaris pauses eye drug trial to resolve ocular inflammation
Mar 11, 2026 6:30am
Science closes major $230M series C round
Mar 5, 2026 10:50am
Preclinical eye disease biotech sets sights on $17M NYSE IPO
Feb 18, 2026 8:55am
Roche drops $100M Kiniksa fibrosis drug from ph. 2 pipeline
Jan 29, 2026 6:29am
